IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v32y2014i2p173-191.html
   My bibliography  Save this article

The Economic Burden of Skeletal-Related Events Among Elderly Men with Metastatic Prostate Cancer

Author

Listed:
  • J. Jayasekera
  • E. Onukwugha
  • K. Bikov
  • C. Mullins
  • B. Seal
  • A. Hussain

Abstract

Metastatic prostate cancer patients with SREs incur higher costs compared to similar patients without SREs. SRE costs among older stage IV (M1) prostate cancer patients vary by SRE type, with spinal cord compression and concurrent surgery costing at least twice as much as other SREs. Copyright Springer International Publishing Switzerland 2014

Suggested Citation

  • J. Jayasekera & E. Onukwugha & K. Bikov & C. Mullins & B. Seal & A. Hussain, 2014. "The Economic Burden of Skeletal-Related Events Among Elderly Men with Metastatic Prostate Cancer," PharmacoEconomics, Springer, vol. 32(2), pages 173-191, February.
  • Handle: RePEc:spr:pharme:v:32:y:2014:i:2:p:173-191
    DOI: 10.1007/s40273-013-0121-y
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.1007/s40273-013-0121-y
    Download Restriction: Access to full text is restricted to subscribers.

    File URL: https://libkey.io/10.1007/s40273-013-0121-y?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Gray, Alastair M. & Clarke, Philip M. & Wolstenholme, Jane L. & Wordsworth, Sarah, 2010. "Applied Methods of Cost-effectiveness Analysis in Healthcare," OUP Catalogue, Oxford University Press, number 9780199227280.
    2. Glick, Henry A & Doshi, Jalpa A & Sonnad, Seema S & Polsky, Daniel, 2007. "Economic Evaluation in Clinical Trials," OUP Catalogue, Oxford University Press, number 9780198529972.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Ian M. McCarthy, 2015. "Putting the Patient in Patient Reported Outcomes: A Robust Methodology for Health Outcomes Assessment," Health Economics, John Wiley & Sons, Ltd., vol. 24(12), pages 1588-1603, December.
    2. Mohsen Sadatsafavi; & Carlo Marra; & Lawrence McCandless & Stirling Bryan, 2012. "The challenge of incorporating external evidence in trial-based cost-effectiveness analyses: the use of resampling methods," Health, Econometrics and Data Group (HEDG) Working Papers 12/24, HEDG, c/o Department of Economics, University of York.
    3. Emelie Heintz & Andreas Gerber-Grote & Salah Ghabri & Francoise F. Hamers & Valentina Prevolnik Rupel & Renata Slabe-Erker & Thomas Davidson, 2016. "Is There a European View on Health Economic Evaluations? Results from a Synopsis of Methodological Guidelines Used in the EUnetHTA Partner Countries," PharmacoEconomics, Springer, vol. 34(1), pages 59-76, January.
    4. Richard M. Nixon & David Wonderling & Richard D. Grieve, 2010. "Non‐parametric methods for cost‐effectiveness analysis: the central limit theorem and the bootstrap compared," Health Economics, John Wiley & Sons, Ltd., vol. 19(3), pages 316-333, March.
    5. Hildegard Seidl & Matthias Hunger & Reiner Leidl & Christa Meisinger & Rupert Wende & Bernhard Kuch & Rolf Holle, 2015. "Cost-effectiveness of nurse-based case management versus usual care for elderly patients with myocardial infarction: results from the KORINNA study," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(6), pages 671-681, July.
    6. Pepijn Vemer & Maureen Rutten-van Mölken, 2013. "The Road Not Taken: Transferability Issues in Multinational Trials," PharmacoEconomics, Springer, vol. 31(10), pages 863-876, October.
    7. Emelie Heintz & Andreas Gerber-Grote & Salah Ghabri & Francoise Hamers & Valentina Rupel & Renata Slabe-Erker & Thomas Davidson, 2016. "Is There a European View on Health Economic Evaluations? Results from a Synopsis of Methodological Guidelines Used in the EUnetHTA Partner Countries," PharmacoEconomics, Springer, vol. 34(1), pages 59-76, January.
    8. David Lairson & Rohan Parikh & Janice Cormier & Wenyaw Chan & Xianglin Du, 2014. "Cost–Utility Analysis of Chemotherapy Regimens in Elderly Patients with Stage III Colon Cancer," PharmacoEconomics, Springer, vol. 32(10), pages 1005-1013, October.
    9. Michael Lebenbaum & Joyce Cheng & Claire Oliveira & Paul Kurdyak & Juveria Zaheer & Rebecca Hancock-Howard & Peter C. Coyte, 2020. "Evaluating the Cost Effectiveness of a Suicide Prevention Campaign Implemented in Ontario, Canada," Applied Health Economics and Health Policy, Springer, vol. 18(2), pages 189-201, April.
    10. Manuel Gomes & Edmond S.-W. Ng & Richard Grieve & Richard Nixon & James Carpenter & Simon G. Thompson, 2012. "Developing Appropriate Methods for Cost-Effectiveness Analysis of Cluster Randomized Trials," Medical Decision Making, , vol. 32(2), pages 350-361, March.
    11. Dyfrig Hughes & Joanna Charles & Dalia Dawoud & Rhiannon Tudor Edwards & Emily Holmes & Carys Jones & Paul Parham & Catrin Plumpton & Colin Ridyard & Huw Lloyd-Williams & Eifiona Wood & Seow Tien Yeo, 2016. "Conducting Economic Evaluations Alongside Randomised Trials: Current Methodological Issues and Novel Approaches," PharmacoEconomics, Springer, vol. 34(5), pages 447-461, May.
    12. Nadia YAKHELEF & Martine AUDIBERT & Bruno PEIRERA & Antoine MONS & Emmanuel CHABERT, 2015. "Cost-utility Analysis of Vertebroplasty versus Thoracolumbosacral Orthosis in the Treatment of Traumatic Vertebral Fractures," Working Papers 201534, CERDI.
    13. Janneke Grutters & Mark Sculpher & Andrew Briggs & Johan Severens & Math Candel & James Stahl & Dirk Ruysscher & Albert Boer & Bram Ramaekers & Manuela Joore, 2013. "Acknowledging Patient Heterogeneity in Economic Evaluation," PharmacoEconomics, Springer, vol. 31(2), pages 111-123, February.
    14. Alexina J. Mason & Manuel Gomes & James Carpenter & Richard Grieve, 2021. "Flexible Bayesian longitudinal models for cost‐effectiveness analyses with informative missing data," Health Economics, John Wiley & Sons, Ltd., vol. 30(12), pages 3138-3158, December.
    15. Nicola E Stanczyk & Eline S Smit & Daniela N Schulz & Hein de Vries & Catherine Bolman & Jean W M Muris & Silvia M A A Evers, 2014. "An Economic Evaluation of a Video- and Text-Based Computer-Tailored Intervention for Smoking Cessation: A Cost-Effectiveness and Cost-Utility Analysis of a Randomized Controlled Trial," PLOS ONE, Public Library of Science, vol. 9(10), pages 1-14, October.
    16. Paddy Gillespie & Eamon O’Shea & Andrew Murphy & Susan Smith & Mary Byrne & Molly Byrne & Margaret Cupples, 2012. "Relative cost effectiveness of the SPHERE intervention in selected patient subgroups with existing coronary heart disease," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(4), pages 429-443, August.
    17. Manuel Gomes & Richard Grieve & Richard Nixon & W. J. Edmunds, 2012. "Statistical Methods for Cost-Effectiveness Analyses That Use Data from Cluster Randomized Trials," Medical Decision Making, , vol. 32(1), pages 209-220, January.
    18. Eric Kaun Santos Silva & June Alisson Westarb Cruz & Maria Alexandra Viegas Cortez Cunha & Thyago Proença Moraes & Sandro Marques & Eduardo Damião Silva, 2021. "Cost-effectiveness in health: consolidated research and contemporary challenges," Palgrave Communications, Palgrave Macmillan, vol. 8(1), pages 1-10, December.
    19. Henry Glick, 2011. "Sample Size and Power for Cost-Effectiveness Analysis (Part 2)," PharmacoEconomics, Springer, vol. 29(4), pages 287-296, April.
    20. Edward C. F. Wilson & George Stanley & Zulfiquar Mirza, 2016. "The Long-Term Cost to the UK NHS and Social Services of Different Durations of IV Thiamine (Vitamin B1) for Chronic Alcohol Misusers with Symptoms of Wernicke’s Encephalopathy Presenting at the Emerge," Applied Health Economics and Health Policy, Springer, vol. 14(2), pages 205-215, April.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:32:y:2014:i:2:p:173-191. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.